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What is already known: -Men have a higher risk of metabolic disease than women until women 
progress through menopause.  
What this review adds: -Information on how inflammatory pathways linked to metabolic 
homeostasis differs between males and females. 
Clinical significance: -Gender is a factor contributing to differences in inflammatory pathways 
linked to metabolic phenotypes. 
-Highlights the need to investigate male and female animals/participants in future research and 
therapy development.    
 
Abstract 
Background and Purpose: Men and women have many differing biological and physiological 
characteristics. Thus, it is no surprise, that the control of metabolic processes and the mechanisms 
underlying metabolic-related diseases have sex-specific components. There is a clear metabolic 
sexual dimorphism in that up until mid-life, men have a far greater likelihood of acquiring cardio-
metabolic disease than women. Following menopause, however, this difference is reduced, 
suggestive of a protective role of the female sex hormones.   
Experimental approach: Inflammatory processes have been implicated in the pathogenesis of 
cardio-metabolic disease with human studies correlating metabolic disease acquisition or risk with 
levels of various inflammatory markers. Rodent studies employing genetic modifications or novel 
pharmacological approaches have provided mechanistic insight into the role of these inflammatory 
mediators.  Sex differences impact inflammatory processes and the subsequent biological 
response.  As a consequence, this may affect how inflammation alters metabolic processes between 
the sexes.  
Key Results: Recently, some of our work in the field of inflammatory genes and metabolic control 
identified a sexual dimorphism in a pre-clinical model and caused us to question the frequency and 
scale of such findings in the literature. This review concentrates on inflammatory-related signalling 
in relation to obesity, insulin resistance and type 2 diabetes and highlights the differences observed 
between males and females.  
Conclusions & Implications: Differences in the activation and signalling of various inflammatory 
genes and proteins presents another reason why studying both male and female patients or animals 
is important in the context of understanding and finding therapeutics for metabolic-related disease.  
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Introduction 
Compared with premenopausal women, men have a higher risk of insulin resistance (S. H. Kim & 
Reaven, 2013; Lee, Ko et al., 2016), type 2 diabetes (Kautzky-Willer, Harreiter et al., 2016), and 
cardiovascular disease (Maas & Appelman, 2010). As women progress through menopause, the 
sex differences in the prevalence of metabolic disease are reduced (Janssen, Powell et al., 2008; 
Maas & Appelman, 2010). Even though obesity is more prevalent in women than men (Kanter & 
Caballero, 2012), a metabolically healthy but obese phenotype seems to be more evident in women 
(Pajunen, Kotronen et al., 2011). Thus, whereas gluteofemoral fat storage is favored in 
premenopausal women, both men and postmenopausal women have increased abdominal fat 
deposition (Abildgaard, Danielsen et al., 2018; Abildgaard, Pedersen et al., 2013; Karastergiou, 
Smith et al., 2012; Lovejoy, Champagne et al., 2008). Distribution of body fat is an important 
determinant for metabolic health (Karpe & Pinnick, 2015). Abdominal fat deposition contributes 
substantially to chronic low-grade inflammation (Schmidt, Weschenfelder et al., 2015) and is 
closely related to the development of type 2 diabetes and cardiovascular disease (Snijder, Zimmet 
et al., 2004; Yusuf, Hawken et al., 2005) whereas gluteofemoral fat deposition is associated with 
an improved metabolic profile (Karpe & Pinnick, 2015; Manolopoulos, Karpe et al., 2010) (see 
depiction in Figure 1 of differences between sexes). Thus, differences in fat deposition are believed 
to contribute substantially to the divergence in inflammatory mediators between sexes.  
 
The metabolically healthy pear-shaped body composition seen in premenopausal women is 
believed to be partly mediated by the female sex hormone, estrogen. Estrogen has been shown to 
increase fat oxidation (Devries, Hamadeh et al., 2005), inhibit lipogenesis (Homma, Kurachi et al., 
2000), and improve adipogenic potential in gluteofemoral adipocytes (Cox-York, Erickson et al., 
2017) and studies in rodents, show that loss of ovarian function leads to a sustained diet-
independent increase in fat mass (Rogers, Perfield et al., 2009; Stubbins, Holcomb et al., 2012; 
Stubbins, Najjar et al., 2012) that is prevented by estrogen supplementation (Gorzek, Hendrickson 
et al., 2007; Stubbins, Holcomb et al., 2012; Stubbins, Najjar et al., 2012). Furthermore, low serum 
estradiol (E2) in middle aged women is associated with increased visceral fat mass and hepatic 
lipid deposition (Abildgaard, Danielsen et al., 2018). Interestingly, oophorectomy (the removal of 
ovaries and therefore the source of estrogen)-induced adiposity in mice seems to be highly 
dependent on decreased physical activity following oophorectomy (Gorzek, Hendrickson et al., 
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2007; Yonezawa, Wada et al., 2012) – a finding that has yet to be replicated in humans. Besides 
improving metabolic function, estrogen seems to prevent low-grade inflammation through direct 
inhibition of leukocyte derived cytokine secretion (Harkonen & Vaananen, 2006; Kramer, Kramer 
et al., 2004; Kramer, Winger et al., 2007), and plasma levels of pro-inflammatory cytokines vary 
throughout the menstrual cycle, showing high levels when estrogen is low and low levels when 
estrogen is high (Bouman, Heineman et al., 2005). Taken together, these studies indicate that 
estrogen plays an important role in immunometabolism and could, in part, be responsible for the 
sex differences in regulation of inflammatory-linked mediators. 
 
Estrogen and receptor signaling 
Estrogen belongs to the family of steroid hormones and signaling is mediated through two 
intracellular estrogen receptors (ER), ERα and ERβ, both belonging to the nuclear receptor family 
of transcription factors (Heldring, Pike et al., 2007). Estrogen signaling is initiated by binding of 
estrogen to the ER and is followed by a cell specific transcriptional response depending on the 
composition of co-regulatory proteins (Katzenellenbogen & Katzenellenbogen, 2002). In recent 
years, a G-protein coupled estrogen receptor (GPER) mediating rapid non-genomic cell signaling 
has also been identified (Filardo, Quinn et al., 2000).  Knock out of the ERα evokes impaired 
adipocyte function and profound insulin resistance - findings closely corresponding to 
oophorectomy (Heine, Taylor et al., 2000; Musatov, Chen et al., 2007), indicating that ERα likely 
mediates many of estradiol’s effects on metabolism. In contrast, ERβ knock out mice show 
decreased ectopic lipid deposition and improved glucose metabolism (Foryst-Ludwig, Clemenz et 
al., 2008) suggesting that the ERα/ ERβ ratio in the specific tissue determines the metabolic effects 
of estrogen (Barros & Gustafsson, 2011). The specific impact of GPER on adipose tissue 
metabolism is more controversial (Barton & Prossnitz, 2015; Prossnitz, Arterburn et al., 2007) but 
GPER selective agonists might improve pancreatic beta-cell function and glucose homeostasis 
(Balhuizen, Kumar et al., 2010; Liu, Kilic et al., 2013). Different estrogen derivatives have been 
shown to have differing affinities to the ER with E2 as the most potent derivative (Kuhl, 2005). In 
fertile, non-pregnant women, E2 is the dominant estrogen primarily produced from the ovaries 
(Simpson, 2003). After menopause, the less potent estrogen derivative estrone (E1) is the most 
abundant, produced from extragonadal sites such as adipose tissue (Hetemaki, Savolainen-
Peltonen et al., 2017). 
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Given the known metabolic gender differences it is, therefore, an important consideration to 
include both genders in the testing of potential novel therapeutics to treat obesity and diabetes. 
Indeed, gender differences are observed in relation to a number of current on the market 
antidiabetic drugs. As reviewed by Franconi and Campesi (Franconi & Campesi, 2014), insulin, 
biguanides, sulfonylureas, thiazolidinediones, glucagon-like peptide-1 receptor agonists, 
dipeptidyl peptidase 4 inhibitors and α-Glucosidase inhibitors all have sex-specific differences in 
relation to either the effectiveness of the treatment, exposure or side-effects that can occur as a 
result of treatment. Quite often in pre-clinical studies of both metabolism and inflammation only 
the one gender is studied (with this gender most commonly being male). This is most commonly 
performed to reduce potential variance due to hormonal fluctuations in the females. Studying just 
the one sex also keeps costs down and as more males are utilized in studies, utilizing males in your 
own studies allows for comparisons between studies more easily. However, this approach may be 
short-sighted and may contribute to missed phenotypes and mechanistic insights.  
 
Recently our work on the genetic alteration of the cytokine Interleukin-18 (IL-18) and its effect on 
metabolism has produced some further interesting findings in relation to sexual dimorphism. This 
further highlighted to us the important role sex has in inflammatory-linked metabolic studies and 
raised the question to us as to how prevalent metabolic sexual dimorphism is in metabolic studies 
of inflammatory-related cytokines. This review aims to highlight the differences observed between 
sexes in pre-clinical genetic models focussing on inflammatory-related processes. 
 
Sex differences in immune function 
Men have higher prevalence and severity of both viral and bacterial infections than women (Klein, 
2000; Roberts, Walker et al., 2001). In contrast, many autoimmune diseases are more common in 
women (Whitacre, 2001). Sex differences in immune function are perceived as multi factorial. It 
is believed, that two X-chromosomes provide females with a more extensive repertoire of proteins 
and thus an increased diversity in the immune response compared to males (Fish, 2008). 
Furthermore, differences in sex hormones are thought to play a causal role. ERs are present on T-
cells, B-cells, macrophages, neutrophils, and NK-cells, among others (Fish, 2008) and estrogen 
increases the number of regulatory T-cells (Arruvito, Sanz et al., 2007), decrease pro-inflammatory 
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cytokine secretion from leukocytes (Kramer, Kramer et al., 2004), and increase the anti-
inflammatory activity of neutrophils (Garcia-Duran, de Frutos et al., 1999). Lastly, gender related 
behavioral aspects influence the prevalence of many infectious diseases. Both cultural, behavioral, 
and anatomical differences between the sexes play a prominent role in the exposure to pathogens 
and whereas women in sub-Saharan Africa are more than twice as likely to be infected with HIV-
1 compared to men (Griesbeck, Scully et al., 2016), men are more likely to suffer from parasitic 
infections (Zuk & McKean, 1996). Altogether, these findings highly implicate the importance of 
considering sex-differences in immune based responses and disease. 
 
Sex differences in metabolic syndrome 
Environmental/lifestyle factors: High energy diets are a major contributing factor to the growing 
obesity and diabetes rates worldwide. Rodent models often use high fat diets (HFD) to simulate 
western diets and related metabolic conditions.  In our hands, when using a HFD-intervention to 
induce obesity and glucose intolerance, we find male mice gain fat mass more rapidly than female 
mice but by the end of a 12-week dietary period both male and female mice, gain similar amounts 
of fat mass (Lancaster, Kraakman et al., 2014). Similar findings are observed with glucose 
tolerance. Male mice are clearly glucose intolerant and have hyperinsulinemia after 4 weeks of 
high fat feeding, whereas female mice are still protected at that timepoint. It is not until more 
chronic high fat feeding has taken place that glucose intolerance and hyperinsulinemia is observed 
in the female mice (Lancaster, Kraakman et al., 2014). Thus, although female mice eventually 
catch up to their male counterparts in terms of adiposity and glucose intolerance, this is delayed 
and there is a period of metabolic protection.  
 
One of the major issues with westernised lifestyles with overindulgence in high caloric food that 
is high in fat and/or sugar and highly processed is that it can provide a source of inflammation to 
metabolic tissues and affect the immune system. Innate immune cells are able to sense, and are 
then activated by, pathogens through pattern recognition receptors (PPRs) which recognize 
exogenous pathogen-associated molecular patterns (PAMPs) (e.g., lipopolysaccharide (LPS)) and 
damage-associated molecular patterns (DAMPs) originating from compromised cells (e.g., 
adenosine triphosphate (ATP), uric acid, heat-shock proteins (HSPs)).  This in turn, leads to the 
activation of innate immune cells (S. Sun, Ji et al., 2012). During the development of metabolic 
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disease, dietary factors could contribute to immune activation from both PAMPs and DAMPs. 
Over the last decade or so it has been recognised that alterations to the gut microbiota (dysbiosis) 
occurs with obesity and/or energy dense, poorly nutritious diets. Overproduction of LPS in this 
setting and increased mobility of this and other PAMPs from the gut through the intestinal barrier 
due to increased gut permeability can increase the exposure of metabolic tissues to inflammatory 
stimuli and initiate or potentiate inflammatory processes. Nutrient excess can be directly sensed 
by the pathogen receptors. Saturated long-chain fatty acids, deleterious lipids such as ceramides, 
as well as glucose and cholesterol have all been shown to activate components of these pathways. 
(Reviewed in (Jin, Henao-Mejia et al., 2013). Immune receptors can also be triggered by the 
production of endogenous DAMPs associated with alterations due to dysregulated metabolism. 
Such signals may include High Mobility Group Box 1 (HMGB1), fetuin, amyloid deposits, 
hyaluronan, and uric acid which are increased in metabolically compromised models and 
individuals and may contribute to the inflammatory milieu (Reviewed in (Jin, Henao-Mejia et al., 
2013). 
 
Sex differences in inflammatory-related metabolic syndrome 
Closely linked to environmental risk factors for obesity and type 2 diabetes is the observation of 
chronic low-grade inflammation in metabolically compromised patients and animal models. 
Circulating and tissue-specific accumulation of pro-inflammatory cytokines has been investigated 
as contributing factors to dysfunctional metabolism and arise due to or a combination of genetic 
predisposition, high caloric intake and sedentary behavior.  
Adipose tissue: The adipose tissue is an important organ in the regulation of metabolism via its 
actions in contributing as an energy storage sink, removing glucose and lipids from the blood-
stream in the post-prandial state, as well as working as an active endocrine gland secreting 
adipokines. Infiltration of immune cells and activation of inflammatory cascades in adipose tissue 
has the potential to disrupt the metabolic actions of the adipose tissue beds and contribute to 
disruption in whole-body metabolic control (Exley, Hand et al., 2014). Interestingly, the induction 
of white adipose tissue expression of many inflammatory and immune related genes such as F4/80 
(macrophage marker), Integrin (CD11c), monocyte chemoattractant protein 1 (MCP1) and tumor 
necrosis factor alpha (TNFα) in response to high fat feeding are markedly down-regulated in the 
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female mice compared to male counterparts (Lancaster, Kraakman et al., 2014).  This reduced 
adipose tissue gene expression of inflammatory cytokines has been recapitulated by others (Singer, 
Maley et al., 2015). Accordingly, oophorectomy of female mice has been shown to induce severe 
adipose tissue inflammation including significant infiltration of macrophages and T-cells, and 
increased protein levels of TNF-α and interleukin 6 (IL-6) (Ludgero-Correia, Aguila et al., 2012). 
This is reflected in general systemic inflammation in the oophorectomized mouse including 
increased plasma levels of TNF-α, IL-6, and IL-18, and general leukocytosis (Cenci, Toraldo et 
al., 2003; Ludgero-Correia, Aguila et al., 2012; Stubelius, Andersson et al., 2017). Furthermore, 
LPS injections leads to increased adipose tissue and plasma IL-6 levels and a more evident fever 
response in oophorectomized mice compared to SHAM control mice (Iwasa, Matsuzaki et al., 
2014), all in all suggesting that loss of ovarian function mediates an increased inflammatory 
response.  
Liver: During obesity, lipid accumulation arises in the liver leading to non-alcoholic fatty liver 
disease (NAFLD). In humans, NAFLD more often affects men; and premenopausal women are 
equally protected from developing NAFLD (reviewed by Ballestri et al (Ballestri, Nascimbeni 
et al., 2017)). It has been suggested that pre-menopausal females are protected against lipid 
accumulation due to partition of fatty acids towards ketone body production rather than very low 
density lipoprotein (VLDL)-triacylglycerol. Equally, oophorectomy leads to lipid deposition and 
estrogen treatment after ovariectomy protects against fatty liver (Zhu, Brown et al., 2013).  At the 
same time oophorectomy also leads to an upregulation of proinflammatory mediators (Inhibitor of 
κB (IκB) kinase (IKK), IL-6, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB)), in the liver, and this is counteracted by estrogen supplementation (Kireev, Tresguerres et al., 
2010; Pighon, Gutkowska et al., 2011), suggesting that the loss of ovarian function also increases 
inflammation in the liver.  
Skeletal muscle: Skeletal muscle is an insulin-sensitive tissue that plays a vital role in the disposal 
of glucose in the post-prandial state. Women have greater insulin-stimulated leg glucose uptake 
than matched men despite having higher intramyocellular triacylglycerol (IMTG) content (L. 
Hoeg, Roepstorff et al., 2009) while increasing lipid levels through lipid infusion results in less 
insulin resistance of skeletal muscle glucose uptake in women than men (L. D. Hoeg, Sjoberg et 
al., 2011). Interestingly, skeletal muscle cells from premenopausal women (high-estrogen 
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environment) showed a lower stress response after prolonged in vitro fatty acid (palmitate) 
treatment compared to skeletal muscle cells from postmenopausal women (low-estrogen 
environment) (Abildgaard, Henstridge et al., 2014). While Torres et al. recently showed, that 
estrogen has a direct impact on the mitochondrial membrane viscosity and improves bioenergetic 
function of the mitochondrion (Torres, Kew et al., 2018), suggesting that the sex mediated 
differences in lipid tolerability could be partly mediated by estrogen.  Although not as highly 
studied, like other peripheral insulin-sensitive tissues, inflammation has been linked to skeletal 
muscle insulin resistance. Skeletal muscle can secrete cytokines and other factors and may become 
inflamed with disrupted metabolism. Likewise, circulating immune cells can infiltrate into the 
muscle bed and increase inflammatory processes potentially contributing to a decrease in insulin 
signaling processes. Despite these common findings, for the purposes of this review we have not 
been able to identify a paper that has made a side by side comparison of skeletal muscle 
inflammatory and immune markers between males and females of any species upon conditions of 
dietary or genetic obesity or other models of dysregulated metabolism. Chronic low-grade 
inflammation may also be important in other metabolic tissues such as the gut, pancreas and the 
brain. 
Sex differences in pro-inflammatory-related mediators 
Interleukins are a subgroup of cytokines that are immunomodulating proteins secreted by the 
immune system in response to stimuli such as infection, trauma and inflammation. They aid in cell 
to cell communication and act in an autocrine, paracrine and endocrine fashion relaying chemical 
messengers.  Once produced and secreted from its cell of origin, interleukins travel to their target 
cell(s) and bind(s) to its receptor where they have been shown to play many physiological 
functions.  They are designated numerically (there are 15 in total) and we will now discuss the 
main interleukins involved in metabolic control and known sex differences in these proteins.  
 
Interleukin 1β (IL-1β): IL-1β has been linked to disturbed metabolic homeostasis in both human 
and animal models. IL-1β concentrations in adipose tissue is increased in diet-induced and 
genetically-induced models of obesity (Stienstra, Joosten et al., 2010). Deletion of its receptor (IL-
1R KO) is protective against HFD-induced insulin resistance (McGillicuddy, Harford et al., 2011) 
while administration of recombinant Il-1β leads to insulin resistance (Wen, Gris et al., 2011). 
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Furthermore, reductions in IL-1β expression is associated with improvement of insulin-sensitivity 
upon weight loss, while elimination of Nlrp3 signaling (the Nlrp3 inflammasome regulates 
caspase-1 activation that allows IL-1β to be released) is beneficial for insulin and glucose tolerance 
(Vandanmagsar, Youm et al., 2011). Deletion of the IL-1 receptor-associated kinase 1 (IRAK-1) 
another pro-inflammatory signaling mediator that acts via IL-1 receptor/Toll-like receptors also 
leads to improved insulin sensitivity (X. J. Sun, Kim et al., 2017). Apart from a calorie restriction 
study (Vandanmagsar, Youm et al., 2011), all these studies were conducted in male mice only and 
there is a scarcity of data in female models that we can identify. Anikinra is a recombinant human 
IL-1 receptor antagonist that has been shown in trials to be beneficial in patients with type 2 
diabetes as it reduces glycated hemoglobin levels (Larsen, Faulenbach et al., 2007). Reduced 
markers of systemic inflammation (C-Reactive protein, and IL-6) were also observed in the 
patients with this treatment compared to placebo (Larsen, Faulenbach et al., 2007). In this trial, 
both male and female patients were enrolled for the study but with far more men (50 compared to 
19). However, there is no breakdown of the treatment effect between sexes to delineate whether 
this IL-1 receptor antagonism was equally effective in both sexes. Even if there was, it is likely to 
be underpowered to determine any real effect due to the lack of female participants compared to 
male in the cohort.  
 
The monoclonal antibody canakinumab which inhibits IL-1β is currently being tested in a large 
clinical trial named the Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
(CANTOS). Despite large reductions in hsCRP and IL-6, canakinumab did not reduce the 
incidence of new-onset diabetes over a median follow up period of 3.7 years. Treatment did reduce 
HbA1c levels compared to placebo during the first 6 to 9 months of the treatment, but no long-term 
benefits on HbA1c or fasting plasma glucose were observed (Everett, Donath et al., 2018) So 
although canakinumab reduces inflammatory levels and lowers cardiovascular event rates 
in patients, it does not seem to lead to the prevention of diabetes among patients with pre-diabetes. 
The study was adjusted for sex in the analysis but no results are displayed to see if either gender 
responded better or worse to this treatment regime.  
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Toll-like receptor (TLR) 4 (a member of the IL-1 receptor superfamily) is a pattern-recognition 
receptor and an important component of the immune system in initiating inflammatory signaling 
via alterations to gene transcription.  It plays a critical role in mediating the response to pathogens 
especially as the receptor for LPS. Metabolic sexual dimorphism is also present in TLR4-/- mice.  
Despite HFD-induced inflammatory gene expression being attenuated in TLR4-/- mice in both 
sexes, whole-body metabolic phenotypes were different. While male TLR4-/- mice were not 
different in comparison to WT mice in terms of body weight, food intake or insulin sensitivity in 
both chow fed and HFD-fed mice there was a distinct phenotype in female mice (Shi, Kokoeva et 
al., 2006). Female mice were fed chow or HFD for a period of 39 weeks. No matter which diet 
was utilised, female TLR4-/- mice were significantly heavier than WT mice with the TLR4-/- mice 
on the HFD almost 10 grams heavier by study end. This increase in weight was due solely to an 
increase in adiposity with lean mass remaining unchanged and was most likely due to an increase 
in food intake as energy expenditure measured in metabolic chambers was not different.   
Despite the typical paradigm that obesity drives insulin resistance, the female TLR4-/- mice were 
more insulin sensitive on insulin tolerance testing (Shi, Kokoeva et al., 2006). Due to the food 
intake data, this study suggested a role for TLR4 in the regulation of food intake but specifically 
in female mice, quite a unique finding that a genetic model with impact food intake in a sex-
dependent fashion. Interestingly, similar to this study, differences upon macrophage-specific 
deficiency of TLR4 were also only observed in female mice, suggesting a sexual dimorphism in 
the effects of macrophage TLR4 expression (Coenen, Gruen et al., 2009). Macrophages have been 
implicated in the development of both insulin resistance and atherosclerosis. Using a bone marrow 
transplantation procedure to delete TLR4 from macrophages (Mθ TLR4-/- mice), the authors 
demonstrated a decrease in macrophage and inflammatory markers in white adipose tissue of 
female chow-fed Mθ TLR4-/- mice compared to Mθ TLR4+/+ mice but not in male mice. This was 
also associated with decreased atherosclerotic lesion area in the females.  Despite this no difference 
was observed in body composition (Coenen, Gruen et al., 2009), nor when mice were challenged 
with a HFD. Thus, under certain metabolic and dietary conditions but only in female mice, TLR4 
may at least in part mediate macrophage accumulation in adipose tissue and vessels.  
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Interleukin 6 (IL-6): IL-6 is a pro-inflammatory cytokine that is somewhat paradoxically found 
elevated in the plasma of obese individuals and linked to the induction of insulin resistance, while 
at the same time identified as a factor that is released from skeletal muscle and associated with 
many of the beneficial metabolic aspects of exercise (reviewed in (Pal, Febbraio et al., 2014)). 
Plasma IL-6 is increased in both rodents and humans with declined ovarian function compared to 
their fertile counterparts (Cioffi, Esposito et al., 2002; Stubelius, Andersson et al., 2017) but the 
specific role of IL-6 in relation to ovarian function is not clear. While traditionally IL-6 was seen 
as a secreted factor from immune cells involved in inflammatory processes, the findings that it is 
released from metabolic organs such as adipose tissue (as an adipokine) (Fried, Bunkin et al., 
1998). and skeletal muscle (myokine) (Steensberg, van Hall et al., 2000) further linked its potential 
importance in metabolic control.  To tease out its role and importance, many genetic mouse models 
of IL-6 have been produced. Whole-body deletion of IL-6 (IL6-/- mice) revealed an obesity 
phenotype and related insulin resistance (Matthews, Allen et al., 2010; Wallenius, Wallenius et al., 
2002). In the initial study by Wallenius and colleagues (Wallenius, Wallenius et al., 2002), both 
sexes were assessed. An increase in adiposity with IL-6 deletion was consistently shown in both 
sexes as well as increased leptin levels and leptin insensitivity (leptin resistance) in older mice. 
IL6-/- female mice displayed an altered circulating lipid profile (increased triglyceride and very-
low density lipoprotein) however, there was no such difference in the lipid profile of the male IL6-
/- mice compared to WT. Decreased glucose tolerance was also observed in the female mice 
however, equivalent data was not provided for male mice (Wallenius, Wallenius et al., 2002). A 
later study did indeed indicate that male IL6-/- mice displayed insulin resistance on chow and HFD 
with concomitant liver inflammation observed (Matthews, Allen et al., 2010). Together, it is likely 
that IL-6 is necessary for the maintenance of weight and glucose homeostasis in both sexes, while 
complete loss of IL-6 plays a role in the regulation of the circulating lipid profile specifically in 
females.  
To determine the impact of tissue-specific loss of IL-6 on metabolism the Hidalgo laboratory has 
conducted numerous studies utilizing cohorts of floxed IL-6 mice to investigate the metabolic 
effect of loss of IL-6 in a particular tissue/organ. Interestingly, many characteristics of these 
models occur in a sex- dependent manner. Deletion of IL-6 in the central nervous system (CNS) 
specifically in astrocytes (Ast-IL-6-/- mice, produced by crossing IL-6 floxed mice with glial 
fibrillary acidic protein promoter driven (GFAP)-Cre mice), led to an progressive increase in the 
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body weight of the Ast-IL-6-/- mice compared to floxed control mice after 8 weeks of age, but only 
in male mice (Quintana, Erta et al., 2013). This was potentially due to a decrease in the activity 
levels of the Ast-IL-6-/- mice. However, as the decrease in activity was seen in both sexes, why 
then the females were protected from weight gain is somewhat of an unsolved story. Associated 
with activity, the male floxed control mice had a decrease in exploratory behavior compared to 
females as measured by total number of head dips and time spent head dipping in a Hole-board 
apparatus test. This defect was completely rescued in the Ast-IL-6-/- male mice while head dipping 
measures remained unchanged in the females (Quintana, Erta et al., 2013). Interestingly there are 
also sex differences observed with transgenic upregulation of IL-6 in astrocytes (GFAP-IL-6 mice) 
(Hidalgo, Florit et al., 2010). Although both sexes were resistant to HFD-initiated obesity, the 
female GFAP-IL6 mice were much more resistant. This corresponded with a drop in the weight of 
the visceral adipose tissue depots in the females where there was no such effect in males.  In fact 
the decrease in weight in the males appeared to have nothing to do at all with the prevention of the 
accumulation of fat mass but instead was due to a decrease in the size of the liver (Hidalgo, Florit 
et al., 2010). Consequently, both the deletion and up-regulation of IL-6 in these cells leads to sex-
specific metabolic phenotypes. 
Another tissue-specific model that has been investigated is the muscle-specific IL-6-/- mouse (mIL-
6-/-). In this instance there were marked differences in the response to the deletion between the 
sexes with opposing body weights observed (Ferrer, Navia et al., 2014). While male mice on both 
a chow control diet and a HFD were protected from weight gain, compared to floxed control mice, 
the female mice were in fact significantly heavier than their floxed controls (Ferrer, Navia et al., 
2014). This was due to an increase in adiposity as the male mIL-6-/- mice had lower gonadal and 
subcutaneous white adipose tissue (WAT) mass as well as lower brown adipose tissue (BAT) mass. 
On the contrary, females displayed higher gonadal and subcutaneous WAT (Ferrer, Navia et al., 
2014). As liver and tibialis muscle weights were not different, this is suggestive that alterations in 
fat pad weights were driving the body weight observation. Food intake was not different between 
the sexes suggesting energy intake was not driving the body composition findings, but in line with 
the body weight findings, male mIL-6-/- mice were more active and females less active than floxed 
controls of each sex in a hole-board test (Ferrer, Navia et al., 2014). From a glucose control 
perspective, male mIL-6-/- mice had decreased blood glucose and insulin levels, whereas females 
did not have differing glucose or insulin concentrations but did have an increase in circulating 
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leptin levels (Ferrer, Navia et al., 2014). To assess glucose control, oral glucose tolerance (oGTT) 
and insulin tolerance tests (ITT) were performed. In line with the body weight phenotype, male 
mIL-6-/- mice tended to have improved glucose excursions on a HFD but these values did not reach 
statistical significance. 
In a follow up study, Molinero and colleagues identified that loss of IL6 in the muscle results in 
lower core body temperature and a higher respiratory exchange ratio (RER) in the light phase (the 
inactive rest phase for a mouse) (Molinero, Fernandez-Perez et al., 2017). Using indirect 
calorimetry it was found that the female mice but not the male mice had an increased energy 
expenditure (Molinero, Fernandez-Perez et al., 2017) which was somewhat conflicting with the 
previous finding of an increased body weight and adipose weight in these female mice. Also 
conflicting was the fact that no physical activity differences were observed in this analysis 
indicating the previous finding of increased activity on the hole-board test may indicate exploration 
rather than activity increases (Molinero, Fernandez-Perez et al., 2017). Nevertheless, these studies 
provide a clear indication of the important interaction between the expression of genes in the 
muscle and sex-specific characteristics and their overall impact on whole-body metabolism. 
The adipose tissue is a vital metabolic organ in that it not only acts as an insulator, an energy 
storage sink and a contributor to post-prandial glucose disposal but is an important endocrine organ 
actively secreting adipokines such as leptin and adiponectin. Many cytokines including IL-6 are 
also adipokines and secreted from the adipose depots throughout the body. Consequently, the role 
of IL-6 specifically derived from the adipose in contributing to metabolic homeostasis is of 
interest. To investigate this, Navia and colleagues generated adipose specific IL-6-/- mice by 
breeding IL-6 floxed mice with aP2-cre mice (aP2-IL6-/-mice) (Navia, Ferrer et al., 2014). Once 
again, in line with the astrocyte and muscle-specific models, sex differences were observed. The 
female aP2-IL6-/-mice fed a HFD put on less weight than their control mice but this effect was not 
observed in the male aP2-IL6-/-mice (Navia, Ferrer et al., 2014). The difference in weight was 
likely due to a decrease in the expansion of both the gonadal and subcutaneous WAT regions, 
although the liver weight was also shown to be lower (Navia, Ferrer et al., 2014). Deficiency of 
adipose IL-6 also decreased fasting circulating insulin and cholesterol levels specifically in the 
female mice. Reminiscent of the mIL-6-/- model, despite the body mass, adipose weight and plasma 
insulin findings (in the female mice), no difference in ITT and GTT’s were observed for either sex 
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(Navia, Ferrer et al., 2014). Together studies into the role of IL-6 in various tissues demonstrates 
a robust sex effect on numerous metabolic parameters.   
A cancer closely linked to compromised metabolic homeostasis and obesity is hepatocellular 
carcinoma (HCC), the most common form of liver cancer. Interestingly this cancer occurs more 
frequently in men, reported to be diagnosed at 3-5 times the rate in males as it is in females (Bosch, 
Thabut et al., 2004). This sexual dimorphism also holds true in animal models of this condition 
(Maeda, Kamata et al., 2005). The development of HCC follows a timeline whereby first there is 
the initial development of hepatic steatosis before the later activation of inflammatory pathways 
in the liver, resulting in an environment conducive to cancer growth. Experimental evidence 
suggest that IL-6 is a critical factor in both the initiation of the cancer and the sexual dimorphism. 
Administration of the chemical carcinogen, diethylnitrosamine (DEN) (which leads to HCC 
development) increases IL-6 levels to a higher degree in males than in females, while loss of IL-6 
neutralises the gender disparity in HCC development (Naugler, Sakurai et al., 2007). Experiments 
designed to test the female sex hormone hypothesis by treating male mice with estrogen were 
successful in reducing IL-6 levels and suppressing liver injury (Naugler, Sakurai et al., 2007).  
Obesity caused by genetic alterations or dietary means also has the capacity to promote hepatic 
inflammation and drive tumorigenesis, a process that involves the induction of IL-6 and the 
activation of the transcription factor linked to cancer development, signal transducer and activator 
of transcription 3 (STAT3) (Park, Lee et al., 2010). 
IL-18: IL-18, a member of the interleukin-1 (IL-1) family, is a cytokine that has been linked to 
alterations in metabolic homeostasis. Clinically, increased levels of IL-18 correlate with metabolic 
syndrome traits such as body mass index (BMI), waist circumference, plasma triglyceride and 
fasting glucose and insulin concentrations in both men and women (Hung, McQuillan et al., 2005), 
suggestive of a role of this cytokine in the pathogenesis of the metabolic syndrome. However, 
genetic manipulation of IL-18 in animal models has revealed the opposite.  Whole-body deletion 
of IL-18 (IL-18-/- mice) or mice who have had the IL-18 receptor alpha knocked out (IL-18r-/-), in 
fact, develop hyperphagia, obesity and insulin resistance (Netea, Joosten et al., 2006). 
Furthermore, mice transgenic for IL-18 binding protein (IL-18BP), a natural antagonist of IL-
18 receptors, also developed insulin resistance (Netea, Joosten et al., 2006). Demonstrating that 
raising IL-18 levels may be metabolically protective, recombinant IL-18 (rIL-18) administered 
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intracerebrally or intraperitoneally inhibited food intake and reversed hyperglycemia (Netea, 
Joosten et al., 2006; Zorrilla & Conti, 2014; Zorrilla, Sanchez-Alavez et al., 2007). In genetically 
manipulating IL-18 signaling, IL-18 receptor alpha knocked was chosen, as IL-18Rα chain, is 
responsible for the extracellular binding of IL-18. Although, mice deficient in the IL-18Rβ chain 
exist; metabolic studies have not been performed. To our knowledge knock-out of both receptors 
does not exist.   
Work from our laboratory has also substantiated these findings and provided further mechanistic 
insight. Treating myotubes in cell culture or skeletal muscle strips with IL-18 activated the critical 
metabolic regulator AMP-activated protein kinase (AMPK) and increased rates of fat oxidation, 
while in vivo electroporation of IL-18 into skeletal muscle to increase its expression also activated 
AMPK and markers of mitochondrial metabolism (Lindegaard, Matthews et al., 2013). Other work 
we were involved with, found that mice lacking the NOD (Nucleotide oligomerization domain)-
like receptor protein 1 (NLRP1) inflammasome have an impaired capacity to produce IL-18 and 
as a consequence phenocopy mice lacking IL-18, with obesity and lipid accumulation observed 
(Murphy, Kraakman et al., 2016). Conversely, mice with an activating mutation in NLRP1, (and 
therefore increased IL-18), have decreased adiposity and metabolic dysfunction (Murphy, 
Kraakman et al., 2016). 
In liver, administration of IL-18 to hepatocyte in vitro reduces the expression of  PEPCK, and basal 
endogenous glucose production is increased in IL-18-/- mice in association to increased 
gluconeogenesis (PEPCK mRNA) (Netea, Joosten et al., 2006). Therefore, it has been suggested 
that IL-18 is involved in controlling basal hepatic glucose production (Netea, Joosten et al., 2006). 
In contrast, we did not find any differences in genes involved in gluconeogenesis (PEPCK or 
glucose-6-phosphat dehydrogenases mRNA) nor in intrahepatic triacylglycerol concentration 
when comparing IL-18R−/− with CON mice irrespective of diet (Lindegaard, Matthews et al., 
2013). A finding which is reproduced by Pazos et al. (Pazos, Lima et al., 2015) Furthermore, even 
though the IL-18R−/− mice are insulin-resistant on an HFD relative to CON mice, there was no 
evidence of impaired insulin signaling or increased lipogenesis (mRNA expression of key fatty 
acid synthesis transcription factors (FAS)/enzyme sterol regulatory–element binding protein-1c  
(SREBP) ) in the liver.  Given that neither hepatic lipid deposition nor the expression of key 
enzymes involved in regulating hepatic glucose production is different when comparing IL-
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18R−/− with CON mice, it is unlikely that changes in liver insulin sensitivity are responsible for 
the reduced whole-body insulin sensitivity observed in IL-18R-/- male mice.  Although, studies 
still need to directly measure insulin sensitivity in the liver. 
While this pre-clinical body of work implicated IL-18 as an important component of metabolic 
regulation, a caveat from these studies were that they were performed entirely on male mice.  
Research into IL-18 in other experimental settings had indicated the potential presence of sex 
divergence in the IL-18 physiological response. Injection of LPS results in significantly higher 
plasma levels of IL-18 in male mice (Aoyama, Kotani et al., 2009). Given this, and the known 
differences between the metabolism of males and females (described above), we set out to 
investigate whether we could repeat our findings in female mice.  We studied female mice with a 
global deletion of the alpha isoform of the IL-18 receptor (IL-18R(-/-)) and their littermate wildtype 
(WT) control mice. Three studies were performed: 1) animals fed a HFD for 16 weeks to simulate 
our previous studies in males; 2) animals were fed a chow diet and aged for 72 weeks to simulate 
a mouse equivalent of post menopause (at this age female mice start to display some similar 
characteristics to postmenopausal women) and 3) animals (3 weeks-old) randomized to either 
bilateral ovariectomy (OVX) or control surgery (SHAM) and followed for 16 weeks to simulate 
depletion of sex hormones. In contrast to male mice, female IL-18R(-/-) mice gained less weight 
and under chow conditions tended to be more insulin sensitive than their WT littermates 
(Lindegaard, Abildgaard et al., 2018). However, with aging IL-18R(-/-) mice showed increases in 
both visceral and subcutaneous fat depots and glucose intolerance was now evident. While 
performing OVX did not affect body weight in IL-18R(-/-) mice, it did exacerbate glucose 
intolerance and impaired liver insulin signaling processes when compared with SHAM control 
mice (Lindegaard, Abildgaard et al., 2018). From these investigations we conclude, that female 
IL-18R-/- mice, only present with a similar metabolic phenotype as reported in male IL-18R(-/-) 
mice if they are exposed to conditions with reduced estrogen such as with aging or after undergoing 
OVX. 
 
Tumor Necrosis Factor –alpha (TNF-α): TNF-α has been proposed to be an important cytokine 
in the pathogenesis of obesity and insulin resistance and is strongly linked to pro-inflammatory 
activation. In a study of 104 patients, the levels of circulating TNF-α were found to be raised in 
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male but not female patients with type 2 diabetes (Pfeiffer, Janott et al., 1997) and postmenopausal 
women show increased TNF-α levels compared to premenopausal women counterparts (Malutan, 
Dan et al., 2014). Animal studies have also identified sex differences regarding this cytokine. TNF-
α mRNA levels in adipose tissue from genetically obese ob/ob male mice (obese due to 
hyperphagia) were threefold higher compared to female ob/ob mice (Neels, Pandey et al., 2006). 
Despite this, in this instance, there was no statistically significant difference in plasma TNF-α 
levels between the sexes. To further investigate the TNF-α pathway, the researchers investigated 
the receptors for TNF-α by genetically deleting them. Deletion of the TNF receptors p55 and p75 
led to an 85% reduction in TNF-α mRNA levels in the adipose tissue of male mice (Neels, Pandey 
et al., 2006). Conversely, loss of the TNF receptors did not affect adipose tissue gene expression 
in female ob/ob mice suggesting that endogenous TNF-α signaling is a regulator of adipose tissue 
TNF-α expression levels in male but not female mice (Neels, Pandey et al., 2006). Further 
differences were observed upon administration of TNF-α to the mice. While this treatment 
increased TNF-α mRNA levels in both sexes, the response was blunted in the females by twofold 
(Neels, Pandey et al., 2006). Overall these data indicate a greater control of TNF-α expression and 
signaling in the female mice. In accordance with this, estrogen supplementation has been shown 
to blunt increases in TNF-α in response to artificially induced endotoxemia in rodents (Hassouna, 
Obaia et al., 2014), further suggesting that this female advantage in TNF-α control could be 
mediated by estrogen.  
Leptin: Leptin is a circulating adipokine produced by adipose tissue. Leptin acts through binding 
to the long form of the leptin receptor (LEPR) which leads to many physiological functions 
including the regulation of appetite and food consumption as well as effects on metabolic rate, 
bone mass, reproductive system and insulin secretion. Along with these effects, leptin also is 
regarded as a proinflammatory factor and participates in innate immunity processes (Abella, 
Scotece et al., 2017). Serum leptin levels are sexually dimorphic in humans (Considine, Sinha et 
al., 1996) and rodents (Landt, Gingerich et al., 1998) however, these sexual dimorphisms are 
reversed between species with human women having higher levels than men, while male rodents 
have higher leptin levels than their female counterparts. The gender difference in humans is likely 
to be due to both a higher proportion of adipose tissue and increased production rate of leptin per 
unit mass of adipose tissue in women (Gutniak, Svartberg et al., 2001). One potential mechanism 
leading to this sexual dimorphism is the influence of steroid hormones on the synthesis of 
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transcripts that encode for leptin.  Experiments in adipocyte-like cells (3T3-L1 murine adipocytes) 
have demonstrated that dihydrotestosterone reduces leptin transcript levels and as a consequence 
the amount of leptin found intracellularly and also the leptin that is secreted from the cell. In 
contrast, 17β-estradiol treatment significantly increases the abundance of transcripts encoding 
leptin and the amount of secreted leptin. Incubating cells with estrogen and androgen receptor 
antagonists had opposite effects on transcript abundance to steroid treatments (Jenks, Fairfield et 
al., 2017). Thus, while it remains to be determined, the sex hormones may play a regulatory role 
in leptin regulation and secretion. Given leptins’ emerging link to inflammatory and immune 
processes, this adipokine may be yet another determinant of inflammatory-linked metabolic 
control and play sex-specific physiological roles.  
Sex differences in anti-inflammatory-related mediators 
Interleukin 10 (IL-10): Contrasting with the previously described pro-inflammatory cytokines, 
IL-10 is a cytokine with potent anti-inflammatory properties. Lower circulating IL-10 
concentration is associated with being overweight or obese in young adolescents (Chang, Chang 
et al., 2013). In healthy adults there is a significant positive association between circulating IL-10 
levels and whole-body insulin sensitivity (Straczkowski, Kowalska et al., 2005) and low IL-10 
production capacity is associated with high plasma glucose, high HbA1c levels, type 2 diabetes, 
and dyslipidemia (van Exel, Gussekloo et al., 2002). Genetic alterations of IL-10 (IL-10KO), IL10 
receptor KO (IL-10RKO) and IL-10 transgenic (IL-10Tg) mice have been generated (Cintra, Pauli 
et al., 2008; Dagdeviren, Jung et al., 2016; Hong, Ko et al., 2009; Kowalski, Nicholls et al., 2011) 
along with studies by which IL-10 is administered as a treatment regime (H. J. Kim, Higashimori 
et al., 2004). Many, but not all, of these models have identified a protective role of IL-10 against 
metabolic disease, however from our analysis we cannot identify any study regarding IL-10 
modulation that has been conducted in female mice and therefore the question remains as to 
whether or not it is of importance in female metabolic processes. Furthermore, both human and 
rodent studies find no changes in plasma IL-10 levels with declining ovarian function (Cioffi, 
Esposito et al., 2002; Ohtani, Garcia et al., 2007) indicating that female sex hormones are less 
likely to have direct impact on systemic IL-10 levels. 
Adiponectin: Adiponectin is an adipocyte-derived secretory protein with profound anti-
inflammatory and insulin-sensitizing functions. High plasma adiponectin levels are believed to 
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reflect healthy adipose tissue and closely reflects improved metabolic flexibility (Scherer, 2016; 
Turer & Scherer, 2012; Wang & Scherer, 2016). Adiponectin secretion from the adipose tissue is 
decreased with increasing central adiposity whereas lower extremity adiposity is associated with 
higher concentrations of adiponectin (Arita, Kihara et al., 1999; Turer, Browning et al., 2012). The 
anti-inflammatory effects of adiponectin are primarily driven through systemic M2 polarization of 
macrophages resulting in a decreased IL-6 and TNF-α release together with an increased secretion 
of IL-10 (Ajuwon & Spurlock, 2005; Kumada, Kihara et al., 2004; Ohashi, Parker et al., 2010).  
Several human studies have shown that women have higher levels of circulating adiponectin 
compared to men, independent of differences in fat mass and insulin sensitivity (Saltevo, 
Kautiainen et al., 2009; Song, Oh et al., 2014). Interestingly, male mice fed a HFD showed 
decreased adiponectin expression in the adipose tissue, compared to chow fed male mice, whereas 
there were no differences in adiponectin expression between chow- and HFD fed female mice, 
despite similar increases in visceral fat mass across sexes (Nickelson, Stromsdorfer et al., 2012). 
This is in accordance with the general perception of healthier adipose tissue and better metabolic 
flexibility in females compared to males (Karastergiou, Smith et al., 2012; Lundsgaard & Kiens, 
2014). A study in pubertal adolescents showed that as testosterone increased in pubertal boys, 
plasma adiponectin levels decreased, whereas plasma adiponectin in pubertal girls remained 
constant (Bottner, Kratzsch et al., 2004). Additional studies report stable plasma adiponectin levels 
during the menstrual cycle (Hall, White et al., 2009; Kleiblova, Springer et al., 2006; Wyskida, 
Franik et al., 2017), altogether suggesting that androgens but not estrogens could regulate plasma 
adiponectin levels.  
Summary 
Overall, this review highlights that metabolic response or control can be altered in a sex-dependent 
manner. Specifically, we have identified and described numerous instances in pre-clinical models 
whereby alterations in genes and proteins linked to inflammatory pathways leads to improved or 
disrupted metabolic control (See Figure 2 for a summary). However, whether phenotypes are 
observed, or the degree to which they are observed, can often be sex-dependent. While traditionally 
all sex differences in physiology were suggested to be due to different regulation in sex hormones, 
these differences could also be attributed to sex-specific behaviors or genetic and epigenetic effects 
caused by the inheritance and unequal dosage of genes located on the X- and Y-chromosomes 
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(Ratnu, Emami et al., 2017).  Investigations of these underlying factors will continue to be an area 
of interest in the metabolic field over years to come. What is clear, is that this review underscores 
the importance of examining both sexes in metabolic studies. Recently, the Reue laboratory 
published a template encompassing considerations for the experimental design of pre-clinical 
studies regarding sex differences in metabolism (Mauvais-Jarvis, Arnold et al., 2017). Adoption 
of such approaches by laboratories will ensure research is undertaken in a way that is considerate 
to these differences and could lead to novel therapeutic targets and potentially even sex-specific 
treatments of metabolic disease in the future.  
 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide 
to PHARMACOLOGY (Harding, Sharman et al., 2018) and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Kelly et al, 2017) 
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Figure 1: Despite obesity being more prevalent in women than men, prior to menopause, women have a reduced risk of metabolic disease. Following menopause and corresponding to an 
increase in deposition of abdominal fat and a decrease in the female sex hormones, metabolic disease risk is increased to similar rates as observed in men.    
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Figure 2: A potential contributor to gender-specific metabolic control is the impact of inflammatory processes. Mechanistic pre-clinical studies using a variety of genetic interventions have 
provided numerous examples of how the male and female metabolic response differs when inflammatory mediators are increased or decreased. Further, many models have not been tested in 
females limiting knowledge in this area.       
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